[go: up one dir, main page]

CA2303132A1 - Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports - Google Patents

Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports Download PDF

Info

Publication number
CA2303132A1
CA2303132A1 CA002303132A CA2303132A CA2303132A1 CA 2303132 A1 CA2303132 A1 CA 2303132A1 CA 002303132 A CA002303132 A CA 002303132A CA 2303132 A CA2303132 A CA 2303132A CA 2303132 A1 CA2303132 A1 CA 2303132A1
Authority
CA
Canada
Prior art keywords
formulations containing
motion sickness
intranasal
intranasal formulations
scopolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002303132A
Other languages
English (en)
Other versions
CA2303132C (fr
Inventor
Jorge C. De Meireles
Vincent D. Romeo
Ramneik Dua
Prafulla K. Chowhan
Charanjit R. Behl
Anthony P. Sileno
Raja G. Achari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303132A1 publication Critical patent/CA2303132A1/fr
Application granted granted Critical
Publication of CA2303132C publication Critical patent/CA2303132C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002303132A 1997-09-11 1998-09-11 Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports Expired - Fee Related CA2303132C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5865197P 1997-09-11 1997-09-11
US60/058,651 1997-09-11
PCT/US1998/018953 WO1999012544A1 (fr) 1997-09-11 1998-09-11 Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports

Publications (2)

Publication Number Publication Date
CA2303132A1 true CA2303132A1 (fr) 1999-03-18
CA2303132C CA2303132C (fr) 2002-07-09

Family

ID=22018094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303132A Expired - Fee Related CA2303132C (fr) 1997-09-11 1998-09-11 Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports

Country Status (5)

Country Link
EP (1) EP1027049A4 (fr)
JP (1) JP2002516815A (fr)
AU (1) AU742878B2 (fr)
CA (1) CA2303132C (fr)
WO (1) WO1999012544A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024116A1 (fr) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Préparations et médications nasales, inhalables et ophtalmiques locales à conservation spontanée
ATE535525T1 (de) 2006-03-31 2011-12-15 Wako Pure Chem Ind Ltd Cyaninfarbstoff vom pyrazoltyp
EP2119797B1 (fr) 2007-01-31 2012-04-11 Wako Pure Chemical Industries, Ltd. Procede de detection d'une amplification ou d'une deletion dans un fragment d'adn genomique
US20250057853A1 (en) * 2023-08-04 2025-02-20 Repurposed Therapeutics, Inc. Compositions and methods for the treatment of motion sickness and emesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164227B (it) * 1983-05-13 1987-04-08 Angeli Inst Spa Composizione farmaceutica atta alla somministrazione nasale di sali quaternari d'ammonio ed attivita' anticolinergica
US7765615B2 (en) * 2007-03-28 2010-08-03 Michael Robert Eastwood Chest protector in sports medicine

Also Published As

Publication number Publication date
AU9385098A (en) 1999-03-29
EP1027049A4 (fr) 2001-09-05
WO1999012544A1 (fr) 1999-03-18
AU742878B2 (en) 2002-01-17
EP1027049A1 (fr) 2000-08-16
JP2002516815A (ja) 2002-06-11
CA2303132C (fr) 2002-07-09

Similar Documents

Publication Publication Date Title
PL319833A1 (en) Compounds and composition for carrying active media
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
SI0725779T1 (fr)
EP0993831A3 (fr) Composés et compositions pour la délivrance d'agents actifs
GR3036622T3 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
AU6819294A (en) Oral drug delivery compositions and methods
CA2339765A1 (fr) Composes et compositions pour l'administration de principes actifs
CA2274485A1 (fr) Compositions medicinales
EP1302207A3 (fr) Procede pour la preparation d'un agent antihypertensif contenant un dipeptide en tant que principe actif
IL111252A0 (en) Dihalopropene compound, insecticide/acaricide containing said dihalopropene compound as active ingredient,and intermediate compound for use in production of said dihalopropene compound
CA2234231A1 (fr) Formulation stabilisante pour le facteur humain de croissance nerveuse
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
CA2163197A1 (fr) Triples complexes de platine
GR3036287T3 (en) Substituted imidazo(4,5-b)pyridines and benzimidazoles as angiotensin II antagonistes.
CA2303132A1 (fr) Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports
PT964865E (pt) Aminas triciclicas farmaceuticamente activas
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
AU5320998A (en) Microparticles containing active substances, agents containing the same, their use in ultrasound-controlled releasing of active substances as well as the method for their production
AU9080398A (en) Novel diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them
RU97112901A (ru) Тромболитические средства
HUP0103623A3 (en) Bispiperidines as antithrombotic agents, their process for preparation and medicament containing them as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed